GDC-9545 giredestrant SERD Genentech structure Drug Hunter Molecules of the Year

selective ER degrader (SERD) + full antag.

oral (30 mg QD), Ph. III for ER+, HER2- BC

from profiling >4k cmpds for desired MoA

giredestrant (GDC-9545)

Genentech, South San Francisco, CA

The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545), is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It…


     this content is exclusive to
    Premium members

    Unlock this content with a Premium membership to read it now.